TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

10 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Dementia / Alzheimer'sParkinson's disease

    PET Imaging Evaluation of [11C]SY08

    Testing a PET scan tracer to detect alpha-synuclein protein clumps in dementia and Parkinson’s

    📍 MGH · Charlestown, MA · Get directions →

    The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

    Testing how drinking ketone drinks affects heart function in people with type 2 diabetes and heart

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Multiple sclerosis (MS)

    Entire-body PET Scans for Multiple Sclerosis

    Testing whether whole-body PET scans can better track MS brain and nerve damage

    📍 Brain Health Alliance · Ladera Ranch, CA · Get directions →

    To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.

    ✓ Study care freeEarly Phase 1Ages 25–55Learn more →
  • Dementia / Alzheimer's

    Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia

    Testing an education and support group for people with progressive aphasia and their caregivers

    📍 University of Texas at Austin · Austin, TX · Get directions →

    The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoeducational support group and an implementation/communication skills training phase on measures of psychosocial function, communicative effectiveness and speech/language function.

    ✓ Study care freeEarly Phase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease

    Testing whether rTMS affects memory and brain function in dementia

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI). This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS).

    ✓ Study care freeEarly Phase 1Ages 40–99Learn more →
  • Multiple sclerosis (MS)

    Effects of Ublituximab on Motor Functions in Multiple Sclerosis

    Testing whether ublituximab changes walking and fall risk in people with relapsing multiple

    📍 Georgia State University · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment.

    ✓ Study care freeEarly Phase 1Ages 18–55Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh cholesterol

    Akkermansia Muciniphilia and Metabolic Side Effects of ADT

    Testing how Akkermansia gut bacteria relate to body and blood lipid changes in people with obesity

    📍 London Health Sciences Centre - Victoria Hospital · London, Ontario · Get directions →

    The overriding objectives of this study are: 1. Primary outcomes: 1.

    ✓ Study care freeEarly Phase 1Ages 18+MenLearn more →
  • Multiple sclerosis (MS)

    Assessment of Synaptic Density in MS

    Testing brain imaging to measure synapse density in progressive MS

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    The investigators propose to use the novel SV2a-PET ligand, \[F-18\]SDM-8 to assess synaptic density in progressive multiple sclerosis (PMS) (including primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS)), given its improved imaging characteristics and potential for large scale applicability. The specific aims of the study are: Aim 1: To compare the cortical and subcortical grey matter synaptic density in PMS patients, patients with relapsing-remitting MS (RRMS), and healthy subjects, using a novel \[F-18\] labeled synaptic density PET ligand, \[F-18\]SDM8, also known as \[F-18\]SynvesT-1.

    ✓ Study care freeEarly Phase 1Ages 18–60Learn more →
  • DepressionDementia / Alzheimer's

    Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

    Testing psilocybin to treat depression in people with early Alzheimer’s or mild cognitive decline

    📍 Johns Hopkins Center for Psychedelic and Consciousness Research · Baltimore, MD · Get directions →

    This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.

    ✓ Study care freeEarly Phase 1Ages 18–85Learn more →
  • Dementia / Alzheimer's

    Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

    Testing glutathione on brain fuel use and inflammation in dementia

    📍 Baylor College of Medicine · Houston, TX · Get directions →

    Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD.

    ✓ Study care freeEarly Phase 1Ages 55–85Learn more →